Last reviewed · How we verify
Active Comparator, Euvichol®-Plus
Euvichol-Plus is an oral cholera vaccine that stimulates immune responses against Vibrio cholerae to prevent cholera infection.
Euvichol-Plus is an oral cholera vaccine that stimulates immune responses against Vibrio cholerae to prevent cholera infection. Used for Prevention of cholera caused by Vibrio cholerae O1 and O139 in endemic and epidemic regions.
At a glance
| Generic name | Active Comparator, Euvichol®-Plus |
|---|---|
| Sponsor | International Vaccine Institute |
| Drug class | Oral inactivated cholera vaccine |
| Target | Vibrio cholerae O1 and O139 antigens |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
Euvichol-Plus is a killed whole-cell oral cholera vaccine combined with recombinant cholera toxin B subunit (rCTB). It works by inducing mucosal and systemic immune responses against the O1 and O139 serogroups of Vibrio cholerae, providing protection against cholera through both antibody and cellular immunity. The vaccine is administered orally and generates intestinal IgA responses that provide local protection at the site of infection.
Approved indications
- Prevention of cholera caused by Vibrio cholerae O1 and O139 in endemic and epidemic regions
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Vomiting
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active Comparator, Euvichol®-Plus CI brief — competitive landscape report
- Active Comparator, Euvichol®-Plus updates RSS · CI watch RSS
- International Vaccine Institute portfolio CI